GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice
Open accessThe DOI matches its Crossref record; 45 of the 47 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Glucagon-like peptide-1 receptor (GLP-1R) agonists are used to treat type 2 diabetes, and transient GLP-1 administration improved cardiac function in humans after acute myocardial infarction (MI) and percutaneous revascularization. However, the consequences of GLP-1R activation before ischemic myocardial injury remain unclear. RESEARCH DESIGN AND METHODS: We assessed the pathophysiology and outcome of coronary artery occlusion in normal and diabetic mice pretreated with the GLP-1R agonist liraglutide. RESULTS: Male C57BL/6 mice were treated twice daily for 7 days with liraglutide or saline followed by induction of MI. Survival was significantly higher in liraglutide-treated mice. Liraglutide reduced cardiac rupture (12 of 60 versus 46 of 60; P = 0.0001) and infarct size (21 ± 2% versus 29 ± 3%, P = 0.02) and improved cardiac output (12.4 ± 0.6 versus 9.7 ± 0.6 ml/min; P = 0.002). Liraglutide also modulated the expression and activity of cardioprotective genes in the mouse heart, including Akt, GSK3β, PPARβ-δ, Nrf-2, and HO-1. The effects of liraglutide on survival were independent of weight loss. Moreover, liraglutide conferred cardioprotection and survival advantages over metformin, despite equivalent glycemic control, in diabetic mice with experimental MI. The cardioprotective effects of liraglutide remained detectable 4 days after cessation of therapy and may be partly direct, because liraglutide increased cyclic AMP formation and reduced the extent of caspase-3 activation in cardiomyocytes in a GLP-1R–dependent manner in vitro. CONCLUSIONS: These findings demonstrate that GLP-1R activation engages prosurvival pathways in the normal and diabetic mouse heart, leading to improved outcomes and enhanced survival after MI in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“These agents exert their anti-atherosclerotic effects through various mechanisms, including by improving blood lipid profiles,444 preserving endothelial integrity and regulating endothelial function,445 as well as modulating inflammatory processes.70”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [445]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 4×
“Glucagon-like peptide-1 (GLP-1), a member of the proglucagon-derived peptide family (2), exerts favorable actions on cardiovascular function in both preclinical and clinical studies.”
BackgroundInfluentialSelf-citationRegulation of cardiac hypertrophy by intracellular signalling pathways
Heineke, J., & Molkentin, J. D. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1983 · Cited by 1,866 · cited 1×
“* ** ** Untreated Liraglutide EX(9-39) Liraglutide +EX(9-39) Forskolin 0 10 20 30 40 50 60”
Ban, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057 · cited 3×
“The GLP-1 metabolite, GLP-1, also exerts cardioprotective actions when administered postischemia (3,16), further highlighting the complexity of different GLP-1–related peptides on the ischemic heart.”
BackgroundSelf-citationJuhaszova, M., Zorov, D. B., Kim, S.-H., Pepe, S., Fu, Q., Fishbein, K. W., Ziman, B. D., Wang, S., Ytrehus, K., Antos, C. L., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19906 · Cited by 1,026
Nikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000120505.91348.58 · Cited by 901 · cited 3×
“A pilot study of GLP-1 administration for 72 h in human subjects with left ventricular (LV) dysfunction after myocardial injury and angioplasty demonstrated reduced hospital stay and improved global and regional LV wall motion scores, benefits that remained detectable even several weeks after hospital discharge (14).”
BackgroundResultGlucagon-like peptide-1 receptor is involved in learning and neuroprotection
During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851 · cited 2×
“* ** ** Untreated Liraglutide EX(9-39) Liraglutide +EX(9-39) Forskolin 0 10 20 30 40 50 60”
ResultSelf-citationHeymans, S., Luttun, A., Nuyens, D., Theilmeier, G., Creemers, E., Moons, L., Dyspersin, G. D., Cleutjens, J. P. M., Shipley, M., Angellilo, A., et al. (1999) · Nature Medicine · doi:10.1038/13459 · Cited by 794 · cited 2×
“* ** ** Untreated Liraglutide EX(9-39) Liraglutide +EX(9-39) Forskolin 0 10 20 30 40 50 60”
BackgroundSokos, G. G., Nikolaidis, L. A., Mankad, S., Elahi, D., & Shannon, R. P. (2006) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2006.08.211 · Cited by 656 · cited 2×
“Similarly, a 5-week course of GLP-1 infusion improved parameters of LV function, functional status, and quality of life in both diabetic and nondiabetic subjects with congestive heart failure (15).”
BackgroundGlucagon-like Peptide 1 Can Directly Protect the Heart Against Ischemia/Reperfusion Injury
Bose, A. K., Mocanu, M. M., Carr, R. D., Brand, C. L., & Yellon, D. M. (2005) · Diabetes · doi:10.2337/diabetes.54.1.146 · Cited by 638
Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis
Li, Y., Hansotia, T., Yusta, B., Ris, F., Halban, P. A., & Drucker, D. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209423200 · Cited by 589
Self-citation
Cited by
Items 201–300 of 592
Li, R., Shan, Y., Gao, L., Wang, X., Wang, X., & Wang, F. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00537 · Cited by 46
Clinical Pharmacology of Incretin Therapies for Type 2 Diabetes Mellitus: Implications for Treatment
Neumiller, J. J. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.04.024 · Cited by 47
The cardiovascular safety of incretin-based therapies: a review of the evidence
Petrie, J. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-130 · Cited by 55
“Consistent with the findings outlined above regarding a cardioprotective effect of native GLP-1 under ischaemic conditions, data from rodent and porcine models indicate that GLP-1 receptor agonists may limit infarct size following ischaemia-reperfusion injury [119-122].”
Ramírez, E., Picatoste, B., Bris, Á. G., Oteo, M., Cruz, F., Caro‐Vadillo, A., Egido, J., Tuñón, J., Morcillo, M. Á., & Lorenzo, Ó. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0643-2 · Cited by 47
“Thus, regulation of main cellular receptors for glucose and/or FA could represent a promising therapeutic target for DCM. Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, has demonstrated insulin dependent and independent cardio-protective actions in DCM by increasing glucagon-like peptide-1 (GLP-1), and follo…”
BackgroundInfluentialvan Genugten, R. E., Möller‐Goede, D. L., van Raalte, D. H., & Diamant, M. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12050 · Cited by 46
“with incretin-based therapies in animal models of (ischaemic) heart disease have shown beneficial effects of these compounds on infarct size and ventricular performance [115] independent of body weight or blood glucose reduction [116].”
BackgroundHesen, N. A., Riksen, N. P., Aalders, B., Ritskes-Hoitinga, M. J., Messaoudi, S. E., & Wever, K. E. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183664 · Cited by 46
“at onset I 500 mg 7wk 2x/d NR NoyanAshraf2009 [34] mouse (C57BL/6J) None m 28d none p.”
BackgroundWang, M., Liu, Y., Liang, Y. T., Naruse, K., & Takahashi, K. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.649785 · Cited by 64
Abot, A., Fried, S. G., Cani, P. D., & Knauf, C. (2021) · Antioxidants and Redox Signaling · doi:10.1089/ars.2021.0100 · Cited by 52
“For example, the GLP-1 receptor agonist liraglutide confers cardioprotective effects from ROS in the hearts of diabetic mice by activating the Nrf-2 pathway (157).”
Incretin-Based Therapy for Prevention of Diabetic Vascular Complications
Mima, A. (2015) · Journal of Diabetes Research · doi:10.1155/2016/1379274 · Cited by 48
“The present reviewwill summarize the relationship betweenmultiple adverse biological mechanisms in diabetes and putative incretin-based therapeutic interventions intended to prevent diabetic vascular complications.”
BackgroundDirect cardiovascular effects of glucagon like peptide-1
Sheikh, A. (2013) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-5-47 · Cited by 45
“This effect was also found to be superior to metformin’s in diabetic mice hearts [56].”
BackgroundBoshchenko, A. A., Маслов, Л. Н., Mukhomedzyanov, А. V., Zhuravleva, O. A., Сергеевна, С. А., Naryzhnaya, N. V., Zinoveva, A., & Ilinykh, P. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094900 · Cited by 46
Hu, E.-H., Tsai, M.-L., Lin, Y., Chou, T.-S., & Chen, T.-H. (2024) · Medicina · doi:10.3390/medicina60030357 · Cited by 43
Gastric bypass surgery: Improving psoriasis through a GLP-1-dependent mechanism?
Faurschou, A., Zachariae, C. O. C., Skov, L., Vilsbøll, T., & Knop, F. K. (2011) · Medical Hypotheses · doi:10.1016/j.mehy.2011.09.011 · Cited by 43
“Besides the established effect in type 2 diabetes, murine studies has thus described cardioprotective and vasodilatory effects of GLP-1 as well as improvement after myocardial infarction [42,43], and in humans with type 2 diabetes and stable coronary artery disease, a beneficial vascular effect of GLP-1 has been repor…”
BackgroundGLP-1 signaling preserves cardiac function in endotoxemic Fischer 344 and DPP4-deficient rats
Ku, H.-C., Chen, W., & Su, M. (2010) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-010-0559-9 · Cited by 45
“Several studies proved that GLP-1 improved outcomes and increased survival rate after myocardial infarction (Ban et al. 2008; Noyan-Ashraf et al. 2009; Ossum et al. 2009).”
Vergès, B. L., & Charbonnel, B. H. (2017) · Diabetes & Metabolism · doi:10.1016/s1262-3636(17)30067-8 · Cited by 44
Myocardial glucotoxicity: Mechanisms and potential therapeutic targets
Battault, S., Renguet, E., Steenbergen, A. V., Horman, S., Beauloye, C., & Bertrand, L. (2020) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2020.06.006 · Cited by 44
Herzlinger, S., & Horton, E. S. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.11.009 · Cited by 46
“In a study in mice with streptozotocin-induced diabetes, pretreatment with liraglutide improved survival after induced myocardial infarction (MI) [25].”
BackgroundInfluentialShao, S., Zhang, X., Xu, Q., Pan, R., & Chen, Y. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108270 · Cited by 46
Huixing, L., Di, F., & Daoquan, P. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2022.12.006 · Cited by 42
Pleiotropic Actions of the Incretin Hormones
McIntosh, C. H. S., Widenmaier, S. B., & Kim, S. (2010) · Vitamins and hormones · doi:10.1016/b978-0-12-381517-0.00002-3 · Cited by 46
Liraglutide: A Review of its Use in the Management of Type 2 Diabetes Mellitus
Perry, C. M. (2011) · Drugs · doi:10.2165/11208110-000000000-00000 · Cited by 45
Ihara, M., Asanuma, H., Yamazaki, S., Kato, H., Asano, Y., Shinozaki, Y., Mori, H., Minamino, T., Asakura, M., Sugimachi, M., et al. (2015) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00835.2014 · Cited by 42
“Therefore, the role of GLP-1 receptor-mediated responses was tested using prosurvival elements involved in cardioprotection: Akt, GSK3 , and Erk1/2 (36).”
MethodImproved diastolic function in type 2 diabetes after a six month liraglutide treatment
Saponaro, F., Sonaglioni, A., Rossi, A., Montefusco, L., Lombardo, M., Adda, G., & Arosio, M. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.04.046 · Cited by 41
“[32] Noyan-Ashraf MH, Momen MA, Ban K, et al.”
BackgroundResultGupta, N. A., Kolachala, V. L., Jiang, R., Abramowsky, C. R., Shenoi, A. N., Kosters, A., Pavuluri, H., Anania, F. A., & Kirk, A. D. (2014) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00210.2014 · Cited by 43
Li, L., Li, S., Liu, J., Deng, K., Busse, J. W., Vandvik, P. O., Wong, E. M., Sohani, Z. N., Bała, M. M., Rios, L. P., et al. (2016) · BMC Cardiovascular Disorders · doi:10.1186/s12872-016-0260-0 · Cited by 41
Bubb, K. J., Kok, C., Tang, O., Rasko, N. B., Birgisdottir, Å. B., Hansen, T., Ritchie, R. H., Bhindi, R., Reisman, S. A., Meyer, C. J., et al. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.04.027 · Cited by 41
“The circumference of the fibrotic infarct area was measured using Image J software (NIH Image) and normalized for left ventricle size as previously described [22].”
MethodFunctional importance of GLP-1 receptor species and expression levels in cell lines
Knudsen, L. B., Hastrup, S., Underwood, C. R., Wulff, B. S., & Fleckner, J. (2012) · Regulatory Peptides · doi:10.1016/j.regpep.2011.12.006 · Cited by 42
GLP-1 Agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies
Yang, H. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14196758 · Cited by 46
“First, they improve myocardial glucose metabolism by enhancing insulin sensitivity and glucose uptake while reducing lipotoxicity through decreased fatty acid oxidation [74].”
Wright, E. J., Farrell, K., Malik, N., Kassem, M. S., Lewis, A. L., Wallrapp, C., & Holt, C. M. (2012) · Stem Cells Translational Medicine · doi:10.5966/sctm.2012-0064 · Cited by 42
Durak, A. T., & Turan, B. (2022) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-022-00939-9 · Cited by 41
“For instance, GLP-1 can acutely increases heart rate, and this effect of GLP-1 on nodal tissue appears to be indirect, mediated via the increased activity of the sympathetic nervous system [26].”
BackgroundGarcia, R. M. R., Uchida, A. H., Rezende, P. C., Lima, E. G., Garzillo, C. L., Favarato, D., Strunz, C. M. C., Takiuti, M. E., Girardi, P. B. M. A., Hueb, W. A., et al. (2012) · Diabetes Care · doi:10.2337/dc12-1495 · Cited by 40
Oral GLP-1 analogue: perspectives and impact on atherosclerosis in type 2 diabetic patients
Saraiva, J. F. K., & Franco, D. R. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01417-0 · Cited by 41
Mondragon, A., Davidsson, D., Kyriakoudi, S., Bertling, A., Gomes-Faria, R., Cohen, P., Rothery, S., Chabosseau, P., Rutter, G. A., & da Silva Xavier, G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104873 · Cited by 37
Nikolic, D., Patti, A. M., Giglio, R. V., Chianetta, R., Castellino, G., Magán-Fernández, A., Citarrella, R., Papanas, N., Janez, A., Stoian, A. P., et al. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01217-z · Cited by 38
“Pre-clinical studies have shown that liraglutide decreases myocardial infarct size by directly acting to reduce intracoronary plaques [20].”
BackgroundQi, Q., Lu, L., Li, H., Yuan, Z., Chen, G., Lin, M., Ruan, Z., Ye, X., Xiao, Z., & Zhao, Q. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s132064 · Cited by 38
“1 Despite their clinical importance, current treatment methods are insufficient for the control of HF after MI. 2 Some accepted treatment methods for MI still have several limitations.”
InfluentialDharmalingam, M., Sriram, U., & Baruah, M. (2011) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.77571 · Cited by 39
“In particular, continuous infusion of liraglutide is associated with an improvement in left ventricular function in patients with acute myocardial infarction and severe systolic dysfunction[38] and in patients with congestive heart failure.[39] The protective effect of liraglutide on ischemic and reperfusion injury, m…”
BackgroundPharmacological management of type 2 diabetes: the potential of incretin‐based therapies
Charbonnel, B. H., & Cariou, B. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01317.x · Cited by 42
“Moreover, promising data have emerged about a cardioprotective role for GLP-1 agonists following MI in mice [133] and humans [134].”
BackgroundAroor, A. R., Manrique‐Acevedo, C., & DeMarco, V. G. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0704-1 · Cited by 38
Chrispal, A., Mathews, K. P., & Surekha, V. (2010) · PubMed · Cited by 45
Huang, J.-H., Chen, Y.-C., Lee, T.-I., Kao, Y.-H., Chazo, T.-F., Chen, S.-A., & Chen, Y.-J. (2016) · Peptides · doi:10.1016/j.peptides.2016.02.007 · Cited by 36
Cao, Y., Chen, Z., Gao, Y., Wang, X.-X., Ma, J., Chang, S., Qian, J., & Ge, J. (2015) · Chinese Medical Journal · doi:10.4103/0366-6999.170259 · Cited by 39
Li, Y., Xu, B., Yang, J., Wang, L., Tan, X., Hu, X., Sun, L., Chen, S., Zhu, L., Chen, X., et al. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105867 · Cited by 36
The role of inflammation in diabetic cardiomyopathy
Reis, F., Nunes, Soares, & Pereira (2012) · International Journal of Interferon Cytokine and Mediator Research · doi:10.2147/ijicmr.s21679 · Cited by 43
“124,125 Experimental and clinical studies 126–128 have suggested that GLP-1 agonists may have a considerable cardioprotective role in the myocardium, although the mechanisms through which GLP-1 acts have not yet been elucidated.”
Giblett, J. P., Clarke, S. J., Dutka, D. P., & Hoole, S. P. (2016) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2016.03.011 · Cited by 35
“Both wildtype and GLP-1R homozygous knockout mice experienced cardioprotection from GLP-1-(7-36) and -(9-36), suggesting the protective effect occurred independent of receptor binding (16).”
BackgroundMethodInfluentialZaccolo, M., & Kovanich, D. (2024) · Physiological Reviews · doi:10.1152/physrev.00013.2024 · Cited by 38
Incretin-based therapies and cardiovascular risk
Mannucci, E., & Dicembrini, I. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.678940 · Cited by 36
Robinson, E., Tate, M., Lockhart, S. M., McPeake, C., O’Neill, K. M., Edgar, K. S., Calderwood, D., Green, B. D., McDermott, B. J., & Grieve, D. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0386-5 · Cited by 39
“In this regard, it is important to note that our chosen experimental approach employing continuous infusion of GLP-1(9–36) commencing immediately after MI or sham surgery, as used in our previous study [18], facilitated specific investigation of direct effects on chronic post-MI remodelling in the absence of indirect…”
ResultSassoon, D., Tune, J. D., Mather, K. J., Noblet, J. N., Eagleson, M. A., Conteh, A. M., Sturek, J. T., & Goodwill, A. G. (2017) · Diabetes · doi:10.2337/db16-1206 · Cited by 36
“This decrease runs counter to previously documented effects of GLP-1 (7-36) administration in the setting of acute myocardial ischemia (2), where preloaddependent increases in CO were accomplished in a GLP1–dependent fashion, reflected by a constant Ees and increased V0.”
BackgroundInfluentialLaviola, L., Leonardini, A., Melchiorre, M., Orlando, M. R., Peschechera, A., Bortone, A. S., Paparella, D., Natalicchio, A., Perrini, S., & Giorgino, F. (2012) · Endocrinology · doi:10.1210/en.2012-1461 · Cited by 39
“Treatment with GLP-1 and GLP-1R agonists has been shown to exert beneficial effects in the setting of ischemic damage, in isolated rodent hearts ex vivo (19, 43), and experimental rat and porcine models in vivo (19, 20), and when experimental diabetes is induced (21).”
BackgroundIncretin Therapies: Effects Beyond Glycemic Control
Mudaliar, S. R. D., & Henry, R. R. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.03.014 · Cited by 37
Exendin-4 ameliorates cardiac ischemia/reperfusion injury via caveolae and caveolins-3
Tsutsumi, Y. M., Tsutsumi, R., Hamaguchi, E., Sakai, Y., Kasai, A., Ishikawa, Y., Yokoyama, U., & Tanaka, K. (2014) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0132-9 · Cited by 35
“Previous studies have demonstrated that the cardioprotective effect of exogenous GLP-1 were attributed to GLP-1R activation and subsequent recruitment of numerous intracellular signaling pathways involving protein kinase B, extracellular regulated kinases, p70S6K, and 5’ adenosine monophosphate-activated protein kinas…”
BackgroundPetersen, K. E., Rakipovski, G., Raun, K., & Lykkesfeldt, J. (2016) · Current Diabetes Reviews · doi:10.2174/1573399812666150918150608 · Cited by 37
Genetic disruption of the Gipr in Apoe−/− mice promotes atherosclerosis
Pujadas, G., Baggio, L. L., Kaur, K. D., McLean, B. A., Cao, X., & Drucker, D. J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101586 · Cited by 34
Self-citationAlasmari, A. F., Ali, N., Alasmari, F. F., Alanazi, W. A., Alshammari, M. A., Al-Harbi, N. O., Alhoshani, A., Sobeai, H. M. A., Alswayyed, M., Alanazi, M. M., et al. (2020) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2020.03.002 · Cited by 34
“Furthermore, it has been shown that the protective effect of LIRA in diabetic mice subjected to myocardial IR injury was chiefly mediated through the activation of Akt (Noyan-Ashraf et al., 2009).”
InfluentialBrown, N. J. (2012) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2012.02.003 · Cited by 34
“Moreover, the metabolite GLP-1 (9-36) improved ischemic injury and caused coronary vasodilation through a nitric oxide–dependent, GLP-1 receptorindependent mechanism.”
BackgroundMethodInfluentialRizzo, M., Nikolić, D., Banach, M., Giglio, R. V., Patti, A. M., Bartolo, V. D., Tamburello, A., Zabbara, A., Pecoraro, G., Montalto, G., et al. (2013) · Clinical Lipidology · doi:10.2217/clp.13.8 · Cited by 34
Tate, M., Chong, A., Robinson, E., Green, B. D., & Grieve, D. J. (2015) · British Journal of Pharmacology · doi:10.1111/bph.12943 · Cited by 33
“…artery ligation, demonstrated reduced infarct development and improved survival compared with those treated with the glucoselowering drug, metformin, suggesting that the observed effects occurred via direct actions on the heart and not secondary to reduced blood glucose (Noyan-Ashraf et al., 2009).”
BackgroundSun, Y., He, L., Yan, M., Zhao, R.-Q., Li, B., Wang, F., Yang, Y., & Yu, H. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.6618 · Cited by 33
“GLP‑1 additionally exerts various effects outside the pancreas, including regulation of food intake and appetite (12), inhibition of gastrointestinal motility and secretion (13) and a cardioprotective effect (14,15).”
Wang, X., Ding, Z., Yang, F., Dai, Y., Chen, P., Theus, S. A., Singh, S. P., Budhiraja, M., & Mehta, J. L. (2016) · Clinical Science · doi:10.1042/cs20160061 · Cited by 33
Incretins and cardiovascular disease: to the heart of type 2 diabetes?
Solini, A., Tricò, D., & Del Prato, S. (2023) · Diabetologia · doi:10.1007/s00125-023-05973-w · Cited by 32
Extra-pancreatic effects of incretin-based therapies
Gallwitz, B. (2014) · Endocrine · doi:10.1007/s12020-014-0223-0 · Cited by 35
Diabetes and Cardiovascular Disease: The Potential Benefit of Incretin-Based Therapies
Addison, D., & Aguilar, D. A. (2010) · Current Atherosclerosis Reports · doi:10.1007/s11883-010-0153-0 · Cited by 36
Nauck, M. A., Tornøe, K., Rasmussen, S., Treppendahl, M. B., & Marso, S. P. (2018) · Diabetes and Vascular Disease Research · doi:10.1177/1479164118783935 · Cited by 32
Vijayakumar, S., Vaduganathan, M., & Butler, J. (2018) · Circulation · doi:10.1161/circulationaha.117.032099 · Cited by 33
Wu, Q., Li, D., Huang, C., Zhang, G., Wang, Z., Liu, J., Yu, H., Song, B., Zhang, N., Li, B., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113517 · Cited by 34
Abbas, N. A. T., & Kabil, S. L. (2017) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-017-1414-z · Cited by 32
“Moreover, Noyan-Ashraf et al. (2009) reported a dosedependent reduction in TNF-α-induced activation of caspase-3 induced by liraglutide in cardiomyocytes in vitro.”
Chen, P., Yang, F., Wang, W., Li, X., Liu, D., Zhang, Y., Yin, G., Lv, F., Guo, Z., Mehta, J. L., et al. (2021) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248420942007 · Cited by 31
“Some studies showed that liraglutide exerts cardioprotective effects in animal and clinical studies.(15,16) Bizino et al reported that liraglutide could reduce the infarct volume and slow the progression of diabetic cardiomyopathy in patients with type 2 diabetes.”
BackgroundExendin-4 ameliorates renal ischemia-reperfusion injury in the rat
Yang, H., Li, H., Wang, Z., Shi, Y., Jiang, G., & Zeng, F. (2013) · Journal of Surgical Research · doi:10.1016/j.jss.2013.06.042 · Cited by 34
Chien, C., Fan, S.-C., Lin, S.-C., Kuo, C., Yang, C., Yu, T., Lee, S., Cheng, D.-Y., & Li, P.-C. (2014) · Thrombosis and Haemostasis · doi:10.1160/th14-03-0258 · Cited by 34
“Moreover, GLP-1 and its GLP-1R agonists reduce the symptoms of experimental myocardial infarction (17) and provide vascular protection in humans with type 2 diabetes and stable coronary artery disease (18).”
BackgroundA Meta-Analysis of the Therapeutic Effects of Glucagon-Like Peptide-1 Agonist in Heart Failure
Munaf, M., Pellicori, P., Allgar, V. L., & Wong, K. (2012) · International Journal of Peptides · doi:10.1155/2012/249827 · Cited by 34
“Work on rats [24, 25], rabbits [26], mice [27], and dogs [28, 29] showed favourable functional effects of GLP-1 in failing hearts with significant improvements in LV systolic and diastolic function.”
BackgroundDiabetes Mellitus in Acute Coronary Syndrome
Stampouloglou, P. K., Anastasiou, A., Bletsa, E., Lygkoni, S., Chouzouri, F., Xenou, M., Κατσαρού, Ο., Theofilis, P., Zisimos, K., Tousoulis, D., et al. (2023) · Life · doi:10.3390/life13112226 · Cited by 40
“Diabetic mice pretreated with liraglutide before the induction of MI showed better survival, reduced infract size, and improved cardiac output [123].”
BackgroundConnelly, K. A., Advani, A., Zhang, Y., Advani, S. L., Kabir, G., Abadeh, A., Desjardins, J., Mitchell, M., Thai, K., & Gilbert, R. E. (2015) · Journal of Diabetes · doi:10.1111/1753-0407.12258 · Cited by 31
“Such studies have produced both positive(40) and neutral findings,(43) reporting effects that may be either dependent or independent of the GLP1R.(36,37,44) The present study specifically sought to address the effects of GLP-1R agonism in a diabetic rodent with permanent coronary artery occlusion, in which, like in th…”
BackgroundVilsbøll, T., & Garber, A. J. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01579.x · Cited by 34
Long-Term Effects of Alogliptin Benzoate in Hemodialysis Patients with Diabetes: A 2-year Study
Nakamura, Y., Inagaki, M., Shimizu, T., Fujita, K., Inoue, M., Gotoh, H., Oguchi, K., & Goto, Y. (2013) · Nephron Clinical Practice · doi:10.1159/000351678 · Cited by 31
Cardiovascular protective effects of GLP-1: a focus on the MAPK signaling pathway
Zhao, Y.-Y., Chen, L.-H., Huang, L., Li, Y., Chen, Y., Zhu, Y., Qu, S., & Zhang, C. (2021) · Biochemistry and Cell Biology · doi:10.1139/bcb-2021-0365 · Cited by 32
Pleiotropic effects of insulin and GLP-1 receptor agonists: Potential benefits of the association
Cariou, B. (2015) · Diabetes & Metabolism · doi:10.1016/s1262-3636(16)30006-4 · Cited by 32
Koshal, P., & Kumar, P. (2016) · Neurochemical Research · doi:10.1007/s11064-016-1890-4 · Cited by 33
Dipeptidyl Peptidase-4 Inhibitor
Murohara, T. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.09.050 · Cited by 32
Owens, D. R., Monnier, L., & Hanefeld, M. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12998 · Cited by 31
“With liraglutide twice daily for 7 days and following the induction of MI, survival was significantly higher in liraglutide-treated mice vs those injected with saline.(87) Furthermore, liraglutide was also OWENS ET AL.”
BackgroundJorsal, A., Wiggers, H., Holmager, P., Nilsson, B., Nielsen, R., Boesgaard, T. W., Kumme, A., Møller, J. E., Videbæk, L., Kistorp, C., et al. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-004885 · Cited by 31
“Furthermore, the GLP-1 analogue, liraglutide, decreased left ventricular structural remodelling and improved cardiac output in mice after occlusion of the left anterior descending coronary artery.(15) Similar results have been shown for the GLP-1 analogue, exenatide.”
ResultCardioprotective effects of incretin during ischaemia-reperfusion
Chinda, K., Chattipakorn, S. C., & Chattipakorn, N. (2012) · Diabetes and Vascular Disease Research · doi:10.1177/1479164112440816 · Cited by 28
Kim, Y. J., Kim, B. H., Choi, B. M., Sun, H. J., Lee, S. J., & Choi, K. S. (2016) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2016.10.002 · Cited by 29
King, N. E., & Brittain, E. L. (2022) · Pulmonary Circulation · doi:10.1002/pul2.12028 · Cited by 30
Okada, K., Kotani, K., Yagyu, H., Ando, A., Osuga, J.-I., & Ishibashi, S. (2014) · Endocrine · doi:10.1007/s12020-014-0246-6 · Cited by 28
Glucagon-like peptide-1 receptor agonists favorably address all components of metabolic syndrome
Chatterjee, S., Ghosal, S., & Chatterjee, S. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i18.441 · Cited by 30
Glucagon-like peptide-1 receptor mediated control of cardiac energy metabolism
Batran, R. A., Almutairi, M. G., & Ussher, J. R. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.005 · Cited by 28
Incretin-based therapies: can we achieve glycemic control and cardioprotection?
Angeli, F. S., & Shannon, R. P. (2013) · Journal of Endocrinology · doi:10.1530/joe-13-0195 · Cited by 30
“2011), and liraglutide (Noyan-Ashraf et al. 2009) improved postischemic contractile dysfunction and decreased infarct size in different in vivo animal models of ischemia and reperfusion.”
BackgroundGlucagon-Like Peptide 1—A Cardiologic Dimension
Treiman, M., Elvekjær, M., Engstrøm, T., & Jensen, J. S. (2010) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2010.02.012 · Cited by 29
“…agonist; liraglutide was not effective in diminishing infarct size in a pig model of focal ischemia (Kristensen et al. 2009), whereas it diminished the frequency of cardiac rupture and infarct size when fed to mice for 7 days before induction of myocardial infarction (Noyan-Ashraf et al. 2009).”
BackgroundYe, Y., Qian, J., Castillo, A. C., Ling, S., Ye, H., Perez-Polo, J. R., Bajaj, M., & Birnbaum, Y. (2012) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00609.2012 · Cited by 29
“However, liraglutide does not increase cAMP levels and Akt and glycogen synthase kinase- phosphorylation in GLP-1R / mice, as it does in wild-type mice (50).”
BackgroundThe use of GLP‐1 receptor agonists in hospitalised patients: An untapped potential
Mustafa, O. G., & Whyte, M. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3191 · Cited by 27
Potential Role of Dipeptidyl Peptidase IV in the Pathophysiology of Heart Failure
Salles, T. A., dos SANTOS, L., Baraúna, V. G., & Girardi, A. C. C. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16024226 · Cited by 28
“Additionally, native GLP-1 attenuates infarct size after ischemia/reperfusion in in vivo and isolated perfused hearts [81], and liraglutide improves myocardial infarction (MI) outcomes in both diabetic and non-diabetic mice [83].”
BackgroundEgom, E. E. A., Mamas, M. A., & Clark, A. L. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.699043 · Cited by 28
“Introduction Plasma glucose concentration often increases in the early hours after the onset of acute myocardial infarction (AMI) both in patients with pre-existing diabetes mellitus and those without [1].”
BackgroundInfluentialDiebold, S., Moellmann, J., Kahles, F., Haj‐Yehia, E., Liehn, E. A., Nickel, A. G., Lebherz, C., Maack, C., Marx, N., & Lehrke, M. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13472 · Cited by 28
“Consistent with the indispensable relevance of the GLP-1 receptor in our model, the GLP-1 metabolite (9-36) failed to increase cardiac contractility 6 hours post permanent LAD ligation (Figure 1P and Figure S1E).”
BackgroundMethodInfluentialQa’aty, N., Wang, Y., Wang, A., Mao, S., Vincent, M. L., Husain, M., & Hinek, A. (2014) · Endocrinology · doi:10.1210/en.2014-1519 · Cited by 27
Self-citationEffects of liraglutide on hemodynamic parameters in patients with heart failure
Zhang, J. Y., Wang, X. Y., & Wang, X. (2017) · Oncotarget · doi:10.18632/oncotarget.18570 · Cited by 26
Zhang, L., Li, C., Zhu, Q., Li, N., & Zhou, H. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7388 · Cited by 29
Gargiulo, P., Savarese, G., D’Amore, C., Martino, F. D., Lund, L. H., Marsico, F., Dellegrottaglie, S., Marciano, C., Trimarco, B., & Filardi, P. P. (2017) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2017.09.006 · Cited by 26
Nauck, M. A., McGuire, D. K., Pieper, K. S., Lokhnygina, Y. V., Strandberg, T. E., Riefflin, A., Delibaşı, T., Peterson, E. D., White, H. D., Scott, R. S., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0921-2 · Cited by 25
Jalil, J., Gabrielli, L., Ocaranza, M. P., MacNab, P., Fernández, R., Grassi, B. A., Jofré, P., Verdejo, H., Acevedo, M., Córdova, S., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084407 · Cited by 28
Cardiovascular Effects of Incretins in Diabetes
Advani, A., Bugyei‐Twum, A., & Connelly, K. A. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.06.010 · Cited by 26
Metadata
- Authors
- Noyan-Ashraf, M. H., Momen, M. A., Ban, K., Sadi, A.-M., Zhou, Y.-Q., Riazi, A. M., Baggio, L. L., Henkelman, R. M., Husain, M., & Drucker, D. J.
- Affiliations
- Toronto General Hospital (CA)
- University of Toronto (CA)
- Mouse Imaging Centre, Department of Medical Biophysics, Hospital for Sick Children, Toronto, Ontario, Canada;
- Hospital for Sick Children (CA)
- Mount Sinai Hospital (CA)
- Corresponding author
- Drucker, Daniel J.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2009-01-16
- Volume
- 58
- Issue
- 4
- Pages
- 975-983
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC2661586
- OpenAlex
- W2150913805
- Cited by
- 575
- References
- 47
- Citations by year
- 2026: 17 · 2025: 25 · 2024: 26 · 2023: 20 · 2022: 21 · 2021: 28 · 2020: 25 · 2019: 25 · 2018: 32 · 2017: 36 · 2016: 33 · 2015: 49 · 2014: 41 · 2013: 47 · 2012: 53
- FWCI
- 35.09
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research (80668)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Ischemia and Reperfusion
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- liraglutide, GLP-1 receptor agonists, myocardial infarction, cardioprotection, diabetic cardiomyopathy, cardiac rupture, infarct size, Akt/GSK-3β signaling, PPARδ, metformin, caspase-3, cyclic AMP
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Animals, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Disease Models, Animal, Heart, Cardiomegaly, Humans, Male, Mice, Inbred C57BL, Myocardial Infarction, Organ Size, Receptors, Glucagon, Mice, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.